June 20, 2010 (FinancialWire) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — Striker Energy Corp. (OTCBB: SKRY) said that it has signed a non-binding letter of intent to acquire all of the assets associated with Granisol (granisetron HCl) Oral Solution from Cypress Pharmaceutical, Inc.

Granisol is used in cancer care to treat nausea and vomiting associated with cancer therapy, as well as post-operative nausea and vomiting. The company said that the drug has been approved for use by the U.S. Food and Drug Administration and is expected to be an immediate source of revenue for Striker following the intended acquisition. Striker plans to implement a commercialization strategy with the objective of improving awareness of Granisol in the United States.

The company said it hopes to reach definitive and final terms with Cypress Pharmaceutical before the end of its fiscal quarter ending August 31, 2010.

Canada-based Striker Energy is engaged in the search for business opportunities in both the healthcare industry and in the oil and gas industry.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [mrgrsacqstns] [cndnexh] [ftrdnwswnd]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.